DXS InternationalAQSE:DXSP Net Margin % is -2.74% as of Apr. 2025. The stock has 2 warning signs investors should review. Among 668 Healthcare Providers & Services companies, DXS International ranks worse than 69.31% on this metric.
The historical rank and industry rank for DXS International's Net Margin % or its related term are showing as below:
AQSE:DXSP'
s Net Margin % Range Over the Past 10 Years
Min: -143.26 Med: 6.59 Max: 13.78
Current: -2.74
AQSE:DXSP's Net Margin % is ranked worse than 69.31% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs AQSE:DXSP: -2.74
DXS International (AQSE:DXSP) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
DXS International Net Margin % Related Terms
DXS International Net Margin % Historical Data
* Premium members only.
The historical data trend for DXS International's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQSE:DXSP vs VEEV, BTSG, TEM: Net Margin % Comparison
For the Health Information Services subindustry, DXS International's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DXS International Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DXS International's Net Margin % distribution charts can be found below:
* The bar in red indicates where DXS International's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DXS International (AQSE:DXSP) has a Net Margin % of -2.74% as of Apr. 2025. Net margin is the ratio of total net income to net sales. View historical data on DXS International and its competitors. According to the industry distribution chart, DXS International ranks #463 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 69.3%.
Is DXS International's Net Margin % too high?
DXS International's current Net Margin % is -2.74%. Based on the distribution chart, DXS International ranks #463 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does DXS International's Net Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DXS International ranks #463 out of 668 companies for Net Margin %. This places DXS International in the lower half of its industry. The industry median Net Margin % is 2.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on DXS International and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DXS International's current Net Margin % is -2.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
Based on GuruFocus' analysis, DXS International (AQSE:DXSP) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 37.5% below its estimated fair value. The current Net Margin % is -2.74%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For DXS International (AQSE:DXSP), the current Net Margin % is -2.74% as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSE:DXSP has been successfully added to your 